Brind.
Entities  /  Company

Tempus.

biotechnology company based in Chicago, Illinois

Seen in 163 reportsLast reported Yesterday

Reports this week
1
Active events
1
Connections
125

What's happening

Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday

One to three months ago

Gone quiet

No new reports in 90+ days

What's reaching Tempus

Events traced to Tempus, step by step, newest first

Explainers that pass through Tempus

Tempus is a step on the way to someone else

Around Tempus this week

News at the entities that move Tempus most

Connections

The 40 strongest of 125, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.
Show all 40 connections
  • Morgan Stanley Transactional

    Morgan Stanley's financial analysis positively influenced Tempus's revenue outlook and potential revenue streams.

    Some supportSep 19
  • Medicare Structural

    Tempus's business model relies on Medicare coverage, reimbursement structures, and indications for its technology to operate and generate revenue.

    Well supportedSep 19
  • SEC Structural

    Tempus is required to file disclosures with the SEC as part of regulatory compliance.

    Some supportJul 31
  • The two entities are currently collaborating in an open-source digital pathology consortium.

    Some supportJun 16
  • Leica Biosystems Operational

    Leica Biosystems has functionally integrated Tempus's AI products into its core platform.

    Some supportSep 26
  • Ark Invest Structural

    Ark Invest holds a 4% weightage of Tempus AI stock as one of its top holdings.

    Well supportedJul 31
  • Nancy Pelosi Transactional

    Nancy Pelosi has held shares in Tempus, with her investment activity influencing market sentiment.

    Some supportJul 31
  • Moderna Operational

    Moderna and Tempus are collaborating partners on the INTerpath-001 clinical trial, which yielded successful Phase 3 results.

    Well supportedSep 8
  • Natera Operational

    Tempus and Natera are direct competitors vying for market share in the ctDNA diagnostics space.

    Some supportSep 8
  • Donald Trump Operational

    A's political platform, specifically regarding tariffs and onshoring, creates a favorable market environment for B's business model.

    Some supportJul 10
  • GSK Structural

    GSK provides essential diagnostic data and AI tools that are utilized by Tempus in its operations.

    Some supportJun 23
  • Raymond James Financial operates by setting price objectives on Tempus AI shares, indicating active market coverage.

    Some supportSep 19
  • Alberta Structural

    Tempus operates as a reporting issuer within the jurisdiction of Alberta.

    Some supportFri 14:30
  • British Columbia Structural

    Tempus is legally required to be a reporting issuer within the jurisdiction of British Columbia.

    Some supportFri 14:30
  • BlackRock Structural

    BlackRock holds a significant financial stake in Tempus, establishing a structural investment relationship.

    Some supportJul 6
  • Toronto Shared context

    Tempus is transitioning investments into the Toronto market for growth.

    Some supportFri 14:30
  • James Rogers Transactional

    CFO James Rogers sold shares of Tempus AI stock.

    Some supportOct 14
  • Jefferies Financial Group provides professional research reports and ratings on Tempus.

    Some supportAug 5
  • Benzinga Mentioned together

    Benzinga reports on Tempus's stock price targets and market status.

    Some supportOct 17
  • AI, Inc. Mentioned together

    Tempus is described as a technology company that utilizes AI to advance precision medicine.

    SpeculativeJul 1
  • BigBear.ai Operational

    The two companies are actively competing for market share and contracts within the artificial intelligence sector.

    Some supportAug 27
  • William P. Blair Mentioned together

    William P. Blair provides market coverage and favorable views on Tempus.

    Some supportJul 21
  • Pfizer Operational

    Pfizer and Tempus are engaged in an ongoing collaboration focused on addressing diagnostic barriers.

    Some supportOct 19
  • Cantor Fitzgerald Mentioned together

    Cantor Fitzgerald initiated research coverage on Tempus AI shares.

    Some supportOct 12
  • Twist Bioscience Mentioned together

    Both companies are noted to operate within the precision medicine and biotech sectors.

    Some supportNov 2
  • Freedom Capital Mentioned together

    Freedom Capital began market coverage and tracking of Tempus AI.

    Some supportJul 10
  • Africa Shared context

    The company operates within the global healthcare technology sector, which includes Africa.

    Some supportJul 22
  • Talkspace Operational

    The companies are compared in the market regarding their viability and growth potential.

    Some supportJun 22
  • MarketBeat Mentioned together

    MarketBeat consistently features Tempus as an AI stock to watch within its sector coverage.

    Well supportedNov 3
  • Ciena Mentioned together

    Both companies were observed experiencing significant daily price movements.

    Some supportOct 7
  • London Shared context

    Tempus conducted a transaction involving the sale of investment properties within London, Ontario.

    Some supportFri 14:30
  • ServiceNow Operational

    Both companies are actively pursuing opportunities within the AI spending market.

    Some supportJul 28

History

Events by the month they began
Show 3 earlier months

June 2026

39 events